BioPharma Credit PLC
BOPCFOTCFinancial Services● Active
$0.91
+$0.91(+82064.72%)
Market Cap$1.0B
P/E Ratio—
52W High$1.02
52W Low$0.8364
BioPharma Credit PLC (BOPCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BOPCF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 23, 2026EPS Actual
$0.05
Revenue
$0.06B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 23, 2026
After Market Close
BOPCF reports quarterly as a OTC-listed Asset Management company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Mar 23, 2026 | — | $0.05 | — | $0.06B | — | — |
| — Q3 FY2025 | Sep 22, 2025 | — | $0.06 | — | $0.08B | — | — |
| — Q1 FY2025 | Mar 25, 2025 | — | $0.04 | — | $0.05B | — | — |
| — Q3 FY2024 | Sep 24, 2024 | — | $0.06 | — | $0.08B | — | — |
| — Q1 FY2024 | Mar 27, 2024 | — | $0.03 | — | $0.06B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.05 | — | $0.08B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.08 | — | $0.14B | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | $0.05 | — | $0.08B | — | — |
Q1 FY2026
Mar 23, 2026
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.06B
Q3 FY2025
Sep 22, 2025
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q1 FY2025
Mar 25, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.05B
Q3 FY2024
Sep 24, 2024
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q1 FY2024
Mar 27, 2024
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.06B
Q2 FY2023
Jun 30, 2023
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q2 FY2022
Jun 30, 2022
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
No analyst estimates available for BOPCF.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Mar 23, 2026 | — | $0.88 | $0.95 | +7.72% |
| — Q3 FY2025 | Sep 22, 2025 | — | $0.92 | $0.93 | +1.63% |
| — Q1 FY2025 | Mar 25, 2025 | — | $0.81 | $0.78 | -3.81% |
| — Q3 FY2024 | Sep 24, 2024 | — | $0.90 | $0.84 | -6.56% |
| — Q1 FY2024 | Mar 27, 2024 | — | $0.90 | $0.92 | +2.29% |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.91 | $1.00 | +9.67% |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.91 | $0.97 | +6.59% |
| — Q2 FY2022 | Jun 30, 2022 | — | No price data | $0.98 | — |
Q1 FY2026+7.72%
Report Date
Mar 23, 2026
EPS Beat/Miss
—
Price Before
$0.88
Price After
$0.95
Q3 FY2025+1.63%
Report Date
Sep 22, 2025
EPS Beat/Miss
—
Price Before
$0.92
Price After
$0.93
Q1 FY2025-3.81%
Report Date
Mar 25, 2025
EPS Beat/Miss
—
Price Before
$0.81
Price After
$0.78
Q3 FY2024-6.56%
Report Date
Sep 24, 2024
EPS Beat/Miss
—
Price Before
$0.90
Price After
$0.84
Q1 FY2024+2.29%
Report Date
Mar 27, 2024
EPS Beat/Miss
—
Price Before
$0.90
Price After
$0.92
Q2 FY2023+9.67%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.91
Price After
$1.00
Q4 FY2022+6.59%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.91
Price After
$0.97
Q2 FY2022—
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
—
Price After
$0.98
Beat Rate0 / 8 quarters
Largest Move+9.67% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BOPCF ends December
BioPharma Credit PLC (BOPCF) most recently reported earnings on March 23, 2026 for Q1 FY2026, posting EPS of $0.05 (in line with the analyst consensus of —). The next BOPCF earnings date is expected around September 1, 2026.
Each quarter, investors track BOPCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BOPCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BOPCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BOPCF earnings · 4 questionsBioPharma Credit PLC's next earnings report is expected around September 1, 2026. BOPCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BOPCF historically reports after market close (AMC).
BOPCF earnings datewhen is BOPCF earningsBOPCF next earnings datewhen does BOPCF report earningsBOPCF earnings calendar
▸ Source: FMP · BioPharma Credit PLC SEC filings · US GAAP · BioPharma Credit PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026